14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ABIO ranks #18258 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

ARCA biopharma Stock Forecast NASDAQ:ABIO

$1.86 (-4.12%)

Volume: 108k

Closed: Jan 26, 2022

Hollow Logo Score: -4.895

ARCA biopharma Stock Forecast

$1.86 (-4.12%)

Volume: 108k

Closed: Jan 26, 2022

Score Hollow Logo -4.895

ARCA biopharma Company Profile

11080 CirclePoint Road

Westminster CO 80020



Industry: Biotechnology

Sector: Healthcare


ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE